Clinical Trials Logo

Clinical Trial Summary

The primary objective is to determine whether continuous sensing, control and mitigation of home indoor air quality influences the frequency of asthma related symptoms, as measured by Serum IgE, Spirometry with exhaled Nitric Oxide, missed school and workdays, need for pharmacologic intervention (albuterol, oral steroids), frequency of sick visits to pulmonologist or primary care provider (PCP), urgent care / emergency department visits, and hospitalizations


Clinical Trial Description

Participants will be in the research study for approximately 2 years. There will be 11 visits to the clinic for monitoring of asthma symptoms and pulmonary function and 16 interval contacts with research staff made by either telephone or email to monitor asthma symptoms. There will also be 5 visits to participants' homes by technicians from Emerson Climate Technologies and/or an electrician in cooperation with Emerson. During these visits Emerson employees will assess participants' homes to determine if they qualify for the study and install study equipment to monitor air quality for the first half of the study and monitor and mitigate air quality for the second half of the study. At the end of the study, the technicians and/or electrician from Emerson will reset the study equipment or replace participants' original equipment, if that is their wish. Participants will be enrolled in the research study for approximately 2 years. The first year, technicians from the study sponsor will install indoor air quality monitoring equipment in the participants' homes and information about the air quality in their home as well as baseline health and asthma information will be collected. This will be done through continuous sensing via an Atmocube air quality sensor, and a portable air quality sensor, the Atmotube. Beginning in the second half of the study, mitigation strategies of a smart home thermostat, the Sensi Touch Smart Thermostat, a smart bath fan control, the Enbrighten Z-wave Switch, and high quality furnace filter, 3M Filtrete MPR 2800 Ultrafine Particle Reduction Air Filter, will be employed. Information about the participants' asthma, health status, and air quality in the homes will continue to be collected. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05843045
Study type Interventional
Source Dayton Children's Hospital
Contact
Status Active, not recruiting
Phase N/A
Start date August 18, 2023
Completion date January 12, 2026

See also
  Status Clinical Trial Phase
Completed NCT02513160 - Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma Phase 3
Active, not recruiting NCT02883530 - Refractory Asthma Stratification Programme (RASP) Bronchoscopy Study
Completed NCT02003521 - Impact of Lung Flute Therapy on Asthma N/A
Completed NCT01253603 - Efficacy, Safety, and Pharmacokinetics of QAW039 Phase 2
Completed NCT01845025 - Study of Safety of Foradil in Patients With Persistent Asthma Phase 4
Not yet recruiting NCT02053402 - Effect of Vitamin D Supplementation on the Control of Asthma in Children at a South African Academic Hospital Phase 4
Completed NCT01156844 - Efficacy, Safety and Pharmacokinetics of Different Regimens of Indacaterol Phase 2
Completed NCT01078688 - Evaluation of the Frequency of Limitation of Activity in Patients With Persistent Asthma N/A
Completed NCT02176694 - Adolescent Controlled Text Messaging to Improve Asthma Medication Adherence in Primary Care N/A
Completed NCT02026336 - E-nose and Inflammatory Asthma Phenotypes N/A
Withdrawn NCT04271839 - Efficiency Control of Fluticasone/Formoterol K-haler (Medium Strength) vs ICS/LABA (High Strength) in Asthma Patients Phase 4
Active, not recruiting NCT04480242 - Asthma Research in Children and Adolescents
Completed NCT02175771 - Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma Phase 3
Completed NCT01147510 - Asthma Control in Elderly Patients With Montelukast Phase 4
Completed NCT03541187 - Cockroach Immunotherapy in Children and Adolescents Phase 2
Completed NCT02040779 - A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma Phase 3